Genentech licenses more ImmunoGen TAP tech
ImmunoGen says that fellow USA-based Genentech has licensed the exclusive right to use its Tumor-Activated Prodrug (TAP) technology with the latter's antibodies to an undisclosed target. This is the fifth such license to be taken by Genentech; in 2000 the company gained exclusive rights to use ImmunoGen's TAP technology with antibodies to HER2 and in 2005 licensed exclusive rights to use the TAP technology with three undisclosed targets.
Daniel Junius, president of ImmunoGen, said: "Genentech is highly visible in their commitment to the field of 'armed antibodies' and has advanced trastuzumab-DM1 - their lead TAP compound - at an impressive rate. We, in turn, continue to make important investments in our technology to retain and enhance our leadership position. We believe the license announced today leverages our complementary expertise."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze